Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation and its executives, alleging they misled investors by inflating sales figures through undisclosed discount programs and overstocking. The lawsuit claims PROCEPT's reported handpiece sales were artificially boosted, creating excess inventory and exposing the company to financial risks. Following disappointing earnings announcements and lowered sales guidance, PROCEPT's stock price dropped significantly. Investors who purchased PROCEPT stock between February 2024 and February 2026 have until September 22, 2026, to seek lead plaintiff status in the case.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
The Vanguard Information Technology ETF (VGT) excludes major tech-adjacent companies like Alphabet (Google), Meta, and Amazon due to a 2018 sector reclassification that moved these firms out of the Information Technology sector. Instead, VGT focuses ...
